Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.
Endogenous retroviruses and multiple sclerosis--new pieces to the puzzle.
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diazepam.
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis.
Focused suggestion with somatic anchoring technique: rapid self-hypnosis for pain management.
Biologics at Novartis
Microbial colonization influences early B-lineage development in the gut lamina propria.
Placebo? no thanks, it might be bad for me!
An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β.
Protective Associations of HDL with Blood Brain Barrier Injury in Multiple Sclerosis Patients.
Investigating Axonal Damage in Multiple Sclerosis by Diffusion Tensor Spectroscopy.
Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide.
Quantitative assessment of multiple sclerosis using inertial sensors and the TUG test.
Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning.
Excess of melanocytic nevi in a patient treated with natalizumab for multiple sclerosis.
Tacrolimus potently inhibits human osteoclastogenesis induced by IL-17 from human monocytes alone and suppresses human Th17 differentiation.
Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features.
Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory.
Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design.
Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis.
Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study.
MP2RAGE Multiple Sclerosis Magnetic Resonance Imaging at 3 T.
Noninvasive molecular imaging of neuroinflammation.
Psychotherapeutic and psychosocial interventions for managing stress in multiple sclerosis: the contribution of mindfulness-based interventions.

Pages